For a pregnant HIV‑positive patient who has achieved a suppressed viral load after antiretroviral therapy, what is the recommended delivery method and intrapartum management, including any additional zidovudine dosing and infant prophylaxis?

Management of HIV-Positive Pregnant Women with Suppressed Viral Load

For a pregnant HIV-positive patient who has achieved viral suppression (viral load <1,000 copies/mL) on antiretroviral therapy, vaginal delivery is appropriate, and the evidence regarding intrapartum zidovudine infusion is increasingly questioned, though most guidelines still recommend it. 1, 2

Delivery Method Based on Viral Load

When viral load is <1,000 copies/mL at 34-36 weeks:

• Vaginal delivery is the recommended route 1, 2
• Cesarean section is NOT required for viral suppression
• The patient's preference should guide the final decision after counseling

When viral load remains ≥1,000 copies/mL at 34-36 weeks:

• Elective cesarean delivery at 38 weeks (before labor onset and membrane rupture) is recommended 1

Intrapartum Management

Maternal Antiretroviral Therapy During Labor

Continue the current HAART regimen throughout labor and delivery 1

Intrapartum Zidovudine - The Controversy

Here's where the evidence becomes nuanced. The older 2007 U.S. guidelines 1 recommend intravenous zidovudine infusion during labor (2 mg/kg loading dose over 1 hour, then 1 mg/kg/hr continuous infusion until delivery) for ALL HIV-positive women, regardless of viral load.

However, more recent evidence challenges this practice when viral load is suppressed:

• A 2022 Italian cohort study of 3,861 pregnancies found that intrapartum zidovudine did NOT influence transmission outcomes in women with HIV-RNA <50 copies/mL 3
• A 2011 UK study demonstrated that intrapartum IV zidovudine <4 hours duration did not increase MTCT risk if viral load was <1,000 copies/mL in patients on HAART 4
• Multiple recent studies (2010-2021) report zero transmission rates with vaginal delivery in virally suppressed women, with variable use of intrapartum zidovudine 5, 6, 7

Clinical Reality: While formal guidelines still recommend intrapartum IV zidovudine, the evidence suggests it may be unnecessary when maternal viral load is <50 copies/mL at delivery. The strongest predictors of transmission in the modern era are:

• Detectable viral load (≥50 copies/mL) 3
• ART discontinuation during pregnancy 3
• Late initiation of ART 4

Infant Prophylaxis

All infants born to HIV-positive mothers should receive:

• Zidovudine for 6 weeks (started within 6-12 hours of birth) 1, 8
• This applies regardless of maternal viral load or delivery method
• Dosing should begin as soon as possible, ideally within 4 hours 6, 7

Postpartum Maternal Management

If the mother does NOT have indications for continued ART for her own health:

• Consider discontinuing therapy after delivery 1
• If regimen includes drugs with long half-lives (e.g., nevirapine), stop NRTIs 3-7 days after stopping the NNRTI to prevent resistance 1

If the mother DOES have indications for treatment (CD4 <350/mm³ or AIDS-defining illness):

• Continue HAART postpartum 1

Key Pitfalls to Avoid

1. Don't assume cesarean section is needed for all HIV-positive women - This is only indicated when viral load is ≥1,000 copies/mL
2. Don't forget infant prophylaxis - Even with undetectable maternal viral load, the infant still needs 6 weeks of zidovudine
3. Don't stop maternal ART during labor - Continue the full HAART regimen throughout delivery
4. Don't delay viral load testing - Check at 34-36 weeks to guide delivery planning

Expected Outcomes

With proper management (suppressed viral load + infant prophylaxis):

• Mother-to-child transmission rate: <1-2% 2, 9
• Multiple recent cohorts report 0% transmission with optimal care 5, 6, 7